caa a22 4500 445354623 CHVBK 20180317142855.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s10238-010-0100-y doi (NATIONALLICENCE)springer-10.1007/s10238-010-0100-y Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome [Elektronische Daten] [Alberto Palazzuoli, Ilaria Quatrini, Anna Calabrò, Giovanni Antonelli, Maria Caputo, Maria Campagna, Beatrice Franci, Ranuccio Nuti] Little is known about the effect of anemia correction with erythropoietin (EPO) on B-type natriuretic peptide (BNP) levels, NYHA class, and hospitalization rate. The aim of the study was to investigate, in patients with cardio-renal anemia syndrome, the effects of EPO on hemochrome and renal function parameters and BNP levels. We also analyzed the effect of EPO therapy on hospitalization rate and NYHA class after 12months in comparison with a population undergoing to standard therapy. We performed a randomized double-blind controlled study of correction of the anemia with subcutaneous α (group A n=13) or β (group B n=14) EPO for 12months in addition to standard therapy with oral iron in 27 subjects. Control group (n=25 patients) received only oral iron. Significant increase in hemoglobin (Hb), hematocrit (Hct), and red blood cells (RBC) were revealed in EPO groups at 12months; Hb, group A 12.3±0.6; group B 11.7±0.8; control group 10.6±0.5g/dl P<0.0001; Hct group A 34.2±2.3, group B 34±2, control group 32.3±1.8% P<0.01; RBC, group A 3.9±0.2, group B 3.8±0.2, control group 3.3±0.2, (P<0.0001). Plasma BNP levels in EPO groups were significantly reduced after 12months (group A: 335±138 vs. group B: 449±274pg/ml control group 582±209pg/ml (P<0.01). After 12months of treatment, hospitalization rate and NYHA class were reduced in EPO groups with respect to control group (P<0.05). Finally, an inverse correlation was observed between BNP and Hb levels in EPO Groups (r=−0.70 P<0.001). EPO treatment reduces BNP levels and hospitalization rate in patients with cardio-renal anemia syndrome. The correction of anemia by EPO treatment appears able to improve clinical outcome in this subset of patients with heart failure. Springer-Verlag, 2010 Anemia nationallicence Erythropoietin nationallicence Heart failure nationallicence B-type natriuretic peptide nationallicence Cardio-renal syndrome nationallicence Palazzuoli Alberto Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Quatrini Ilaria Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Calabrò Anna Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Antonelli Giovanni Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Caputo Maria Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Campagna Maria Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Franci Beatrice Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Nuti Ranuccio Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut Clinical and Experimental Medicine Springer Milan 11/1(2011-03-01), 43-48 1591-8890 11:1<43 2011 11 10238 https://doi.org/10.1007/s10238-010-0100-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10238-010-0100-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Palazzuoli Alberto Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Quatrini Ilaria Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Calabrò Anna Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Antonelli Giovanni Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Caputo Maria Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Campagna Maria Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Franci Beatrice Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 700 1- Nuti Ranuccio Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100, Siena, Italy aut NATIONALLICENCE 773 0- Clinical and Experimental Medicine Springer Milan 11/1(2011-03-01), 43-48 1591-8890 11:1<43 2011 11 10238 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer